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Summary
Protein kinase C (PKC) is a key regulatory enzyme that has been implicated as a molecular target for the action of general anaesthetics. We have determined the effects of halothane on the translocation and down-regulation of conventional PKC (cPKC) by analysing the subcellular distribution of PKC activity, [ 3 H]phorbol-12,13-dibutyrate ([ 3 H]PDBu) binding and PKC immunoreactivity in intact rat cerebrocortical synaptosomes, a subcellular fraction that contains functional nerve terminals. Halothane alone (2.4 vol%) reduced membrane-associated (P:0.05) and increased cytosol (P:0.01) PKC activity, while phorbol-12-mristate, 13-acetate (PMA) 0.1 mol litre
91
, a metabolically stable activator of PKC, reduced membrane (P:0.01) without altering cytosol PKC activity. Halothane and PMA in combination reduced membrane PKC activity to undetectable levels and reduced cytosol PKC activity (P:0.01). Halothane alone had no significant effects on the distribution of [ 3 H]PDBu binding, while PMA alone significantly reduced both membrane and cytosol [ 3 H]PDBu binding (P:0.01). Halothane and PMA in combination reduced membrane and cytosol [ 3 H]PDBu binding further, but this effect was not significantly different from the effect of PMA alone. Experiments using isoform-selective antibodies to PKC␣, PKC␤ or PKC␥ demonstrated synergistic interactions between halothane and PMA in promoting translocation of the three conventional PKC isoforms from the cytosol to the membrane fraction of synaptosomes and downregulation of their immunoreactivity. Halothane and PMA together reduced cytosol PKC␣/␤/␥ immunoreactivity significantly more (P:0.05) than PMA alone. Halothane thus has two distinct actions on PKC in synaptosomes: activation of endogenous PKC activity and potentiation of activation-induced cPKC translocation and downregulation. These potentially competing effects may underlie some of the conflicting results obtained with halothane on PKC-mediated processes in intact cells. (Br. J. Anaesth. 1997; 78: [189] [190] [191] [192] [193] [194] [195] [196] Protein kinase C (PKC) is an important family of protein kinases that regulates neuronal function. 1 2 Many studies have implicated PKC as a potential target for general anaesthetic effects in various tissues. [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] PKC exists as a number of structurally related isoforms distinguished by their regulatory domains and cofactor dependence [18] [19] [20] : the conventional PKC isoforms (cPKC: ␣, ␤1, ␤2 and ␥) are activated by Ca 2; , diacylglycerol and phorbol esters; the new PKC isoforms (nPKC: ␦, ⑀, and ) do not require Ca 2; but are activated by diacylglycerol and phorbol esters; and the atypical PKC isoforms (aPKC: , , and PKC I ) do not require Ca 2; or diacylglycerol for activity and are not affected by phorbol esters.
Physiological activation of cPKC isoforms, which are abundant in mammalian brain, 19 occurs when diacylglycerol is generated in response to activation of cell surface receptors coupled to activation of phospholipase C or in response to Ca 2; -induced activation of phospholipase D. 1 21 Binding of diacylglycerol increases the affinity of cPKC for Ca 2; and phosphatidylserine, facilitates cPKC translocation and binding to cell membranes, and increases cPKC catalytic activity. 22 Phosphorylation of specific proteins by activated PKC is the effector mechanism for regulation of several neuronal processes, 2 many of which are also sensitive to general anaesthetics, such as neurotransmitter release, 23 ion channel function 24 and neurotransmitter receptor desensitization. 25 On agonist-induced stimulation of a number of cell types, cPKC and nPKC, but not aPKC, isoforms 26 rapidly translocate from the cytosol to the membrane where they undergo proteolysis-mediated downregulation in an isoform-specific manner. 27 28 The role of these important regulatory mechanisms in determining the ultimate effects of anaesthetics and other drugs on the PKC signalling pathway in specific tissues and cells is unknown.
Previous studies of general anaesthetic effects on PKC activity have yielded contradictory results. For example, halothane has been found to inhibit 13 or stimulate 14 purified brain PKC in vitro, and to stimulate PKC activity in brain cytosol, 6 in synaptosomes 15 and in intact neurosecretory cells. 9 These differences may be explained in part by variations in the conditions used to analyse PKC activity in vitro, 14 or by differences in the particular PKC isoforms present. PKC has been implicated in the effects of general anaesthetics on neurotransmitter release from PC12 cells, 9 prostacyclin production in endothelial cells, 16 protein phosphorylation in neuronal growth cones, 12 smooth muscle contraction, 10 hepatic blood flow 17 and loss of righting reflex in tadpoles. 11 Several of these studies inferred anaesthetic inhibition, rather than activation, of PKC activity based on indirect evidence. We now report evidence that halothane can potentiate cPKC translocation and down-regulation induced by phorbol ester treatment in synaptosomes. The results provide a potential mechanism for biphasic effects of halothane on PKC activity in intact cells: initial stimulation of PKC activity as a result of a direct effect on enzymatic activity, 15 followed by alterations in PKC-dependent processes caused by PKC translocation and down-regulation.
Materials and methods

SYNAPTOSOME PREPARATION AND INCUBATION
Synaptosomes were prepared from rat cerebral cortex by the method of Dunkley, Jarvie and Heath, 29 as described previously, 30 and were stored as pellets on ice for up to 4 h until use. Synaptosome pellets were resuspended to a protein concentration of 2 mg ml 91 (determined by the method of Bradford 31 with bovine serum albumin as standard) in incubation medium containing the following (mmol litre 91 ): NaCl 140, KCl 5, NaHCO 3 5, MgCl 2 1, D-glucose 10 and HEPES (4-(2-hydroxyethyl)-1-piperazine ethanesulphonic acid) 10, at pH 7.4 with NaOH containing 1 mg ml 91 of fatty acid-free bovine serum albumin) equilibrated with 95% oxygen-5% carbon dioxide (v/v). After a 5-min incubation period in a shaking water bath at 37 ЊC to allow ion gradient re-equilibration, CaCl 2 1 mmol litre 91 was added to a 1-ml aliquot of synaptosomes. After another incubation period of 1 min, halothane, phorbol-12-myristate, 13-acetate (PMA) or drug vehicle (dimethyl sulphoxide; DMSO) was added where appropriate. Translocation reactions were carried out in 8.8 ml glass vials sealed with Teflon/silicone septa, through which liquid halothane (1-2 l, either pure or diluted with DMSO, injected onto the side of the vial to vaporize) was injected directly with a Hamilton microsyringe. Final vapour phase halothane concentrations, which equilibrate by 2 min, 32 were measured in similar samples by gas chromatography. 33 The incubation was continued for another 10 min, after which the reaction mixtures were transferred rapidly to polycarbonate centrifuge tubes on ice and centrifuged at 9000 g for 5 min at 4 ЊC.
SYNAPTOSOME FRACTIONATION
After incubation synaptosomes were fractionated by a modification of the method of Diaz-Guerra and colleagues. 34 The synaptosome pellet was lysed immediately in 2 ml of ice-cold hypotonic lysis buffer (HEPES 10 ) by homogenization with a glass/Teflon homogenizer for five up-and-down strokes. The homogenate was centrifuged at 200 000 g for 15 min at 4 ЊC to yield supernatant ("cytosol") and pellet ("membrane") fractions, which were separated. The pellet fraction was resuspended in 1 ml of lysis buffer containing 0.5% (v/v) Nonidet P-40 by homogenization and incubated on ice for 30 min to extract PKC activity. An additional 1 ml of lysis buffer was added to dilute the detergent concentration, the pellet was centrifuged at 200 000 g for 15 min at 4 ЊC, and the supernatant fraction ("membrane extract") was removed. The cytosol and membrane extract fractions were then filtered through 1-ml (bed volume) columns of DEAEcellulose (DE-52, Whatman) equilibrated in lysis buffer to remove endogenous PKC inhibitors 35 and detergent. The columns were washed with 4 ml of lysis buffer, followed by 2 ml of lysis buffer containing NaCl 0.1 mol litre 91 to elute PKC activity. The samples containing PKC were then concentrated and their buffer changed to HEPES 10 mmol litre 91 , pH 7.5, with a Centricon-30 concentrator (Amicon, Inc., Beverly, MA, USA) The concentrated samples were adjusted to equal volumes and protein concentrations were measured by the method of Bradford. 14 The reaction mixture, containing all assay components except ATP, was equilibrated for 5 min, after which reactions were initiated by addition of ATP and terminated after 5 min by addition of glacial acetic acid 10 l. Histone phosphorylation was determined by the phosphocellulose paper method as described previously. 14 At least two concentrations of each synaptosome extract were analysed to ensure that the reaction was in the linear range. Each assay was performed in triplicate in the absence and presence of the selective PKC inhibitor peptide PKC 19 
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; Amersham) in 2.5% non-fat dry milk and 0.05% Tween 20 in immunoblot buffer for 1.5 h, and with immunoblot buffer overnight followed by twice for 5 min. The PKC immunoreactive bands were examined by autoradiography and quantified by scanning and analysis with a PhosphorImager autoradiography system (Molecular Dynamics, Sunnyvale, CA, USA).
Thymol-free halothane was a gift from Halocarbon Products (River Edge, NJ, USA). The PKC inhibitor peptide (PKC [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] [36] , 36 synthesized by the Rockefeller University Protein Sequencing Facility, was a gift from A. J. Czernik (Rockefeller University). Nonidet P-40, Tween 20 and sodium dodecyl sulphate were from Pierce Chemical Co. (Rockford, IL, USA). PMA and PDBu were from LC Laboratories (Woburn, MA, USA). Bovine serum albumin (fatty acid-free) was from Sigma (St Louis, MO, USA). 
Results
PKC ACTIVITY
The relative content of PKC enzymatic activity in fractionated rat cortical synaptosomes is shown in table 1. The synaptosomal membrane fraction contained a higher specific activity of PKC (defined as PKC [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] [36] -sensitive histone H1 activity) than the cytosol fraction under basal conditions, which is consistent with the results of previous studies. 34 41 Treatment with phorbol esters has been shown to induce translocation of cytosolic PKC activity and down-regulation of membrane PKC activity in crude 27 and purified 34 synaptosomes. Exposure of intact purified synaptosomes to PMA 0.1 mol litre 91 for 10 min resulted in a significant reduction in membrane PKC activity with no change in cytosol PKC activity. Exposure of synaptosomes to 2.4 vol% halothane for 10 min also reduced membrane PKC activity, although not as much as PMA alone, but increased cytosol PKC activity. Exposure of synaptosomes to both PMA and halothane further reduced membrane PKC activity to undetectable levels and significantly reduced cytosol PKC activity compared with control, PMA alone or halothane alone.
PHORBOL ESTER BINDING
Phorbol esters bind to the regulatory domains of and activate cPKC and nPKC, but not aPKC. 27 Isoform-selective antibodies to PKC were used to determine the distribution of cPKC␣, ␤ and ␥ immunoreactive protein in control and treated synaptosomes by immunoblotting ( fig. 2 ). All three (table 2) . The relative amounts of the three cPKC isoforms in purified rat cerebrocortical synaptosomes detected with these antibodies (PKC␣9PKC␥99PKC␤) do not reflect the actual relative amounts caused by differences in antibody cross-reactivity. Treatment with PMA induced both translocation of all three isoforms of PKC from the cytosolic to the membrane fraction (evident in the significant increase in membraneassociated PKC) and down-regulation of PKC (evident in the reduced cytosolic and total PKC). The effect of PMA on PKC␥ was less marked. This is consistent with a previous study that showed PKC␥ to be less sensitive to PMA-induced translocation and down-regulation than PKC␣ or PKC␤. 27 Halothane caused a small reduction in cytosolic PKC␣ and an increase in cytosolic PKC␤. Combined treatment with halothane and PMA resulted in synergistic reductions in the cytosolic levels of all three cPKC isoforms. There were no significant changes in membrane levels, although total immunoreactivity was reduced; this indicates an increase in both translocation and degradation of PKC, as proteolysis occurs primarily with the membrane bound, and not the cytosolic, form of the enzyme.
Discussion
Most neurones in the CNS contain the ␣, ␤ and/or ␥ subspecies of the cPKC isoforms. 19 47 PKC␣ and PKC␤ are expressed in both CNS and peripheral tissues, while PKC␥ is restricted to the brain and adrenal glands. 19 Within the CNS, PKC␥ and PKC␤1 are found predominantly in nerve terminals and growth cones, while PKC␥ and PKC␤2 are predominantly postsynaptic 19 43 44 ; cortical synaptosomes contain PKC␣, PKC␤ and PKC␥. 44 The relative abundance and function of the nPKC or aPKC isoforms in synaptosomes have not been determined. Activation of PKC in synaptosomes or cultured neurones by diacylglycerol or tumourpromoting phorbol esters (long-acting agents that mimic the effects of diacylglycerol, which is rapidly metabolized) results in "translocation" of cPKC from the cytosol to the membrane fraction. Persistent activation of cPKC by diacylglycerol or phorbol esters results in "down-regulation" of PKC as a result of proteolysis with loss of enzyme activity and immunoreactivity. PMA causes an increase in particulate (membrane-associated) PKC activity ("translocation") at low doses (10 nmol litre 91 ) followed by a dose-and time-dependent decrease in both cytosolic and particulate PKC activity ("down-regulation") in synaptosomes. 34 Phorbol ester-induced translocation of cPKC in synaptosomes has been analysed previously by enzyme activity and phorbol ester binding measurements. 27 34 In this study we have compared the effects of phorbol ester or halothane, or both, on PKC translocation and down-regulation by three independent methods of PKC analysis: enzyme activity, phorbol ester binding and immunoblotting. Down-regulation of membrane PKC was the predominant effect of phorbol ester treatment observed for both PKC activity and [ 34 ) and the presence of endogenous phorbol ester binding competitors. Possible artefacts affecting measurement of PKC immunoreactivity include lack of antibody specificity and PKC degradation by proteolysis, the latter of which could also affect the two other methods. However, no immunoreactive breakdown products were detected in the immunoblots. Together these data indicate that caution is required in comparing the results of studies of PKC subcellular distribution determined by different methods. 28 The discrepancy between the activity measurements and [ 3 H]PDBu binding or immunoreactivity may reflect interactions between PKC and inhibitory regulatory protein(s) that modulate PKC activity in the membrane or cytosol, or both. 35 We did not detect an effect of halothane on equilibrium [ 3 H]PDBu binding in synaptosomes. Activation of purified rat brain PKC by PDBu in vitro is also insensitive to halothane (unpublished observations). Our previous studies showed that halothane increases the sensitivity of PKC to activation by diacylglycerol, an endogenous PKC activator that binds to the same site in the regulatory domain of PKC as phorbol esters. 45 These results suggest that the interactions with PKC of phorbol esters and diacylglycerol differ in their sensitivity to halothane.
Halothane alone had no significant effects on PKC translocation or down-regulation measured by [ 3 H]PDBu binding or PKC immunoreactivity using the selective antibody to PKC␥. However, significant reproducible effects of halothane were observed on cytosol PKC activity and on cytosol PKC␣ and PKC␤ immunoreactivity. Overall, the effects of 2.4 vol% halothane (which is close to its EC 50 for activation of purified PKC and is 2.3 times the MAC at 37 ЊC in rat 46 ) on PKC distribution determined by the three methods were not consistent. In contrast, the combination of 2.4 vol% halothane and PMA 0.1 mol litre 91 consistently reduced cytosolic PKC␣/␤/␥ immunoreactivity (increased PKC translocation) compared with treatment using PMA or halothane alone. The combination also reduced membrane PKC (increased PKC down-regulation) when measured by PKC activity, although this effect was not evident with [ 3 H]PDBu binding or the isoform-selective PKC antibodies. The enhanced translocation of PKC induced by halothane does not appear to involve a change in the ability of PKC to bind phorbol ester. This suggests that halothane stimulates the translocation process itself, perhaps by increasing the affinity of activated PKC for its membrane receptor.
We have shown previously that halothane and propofol stimulate purified PKC activity in vitro 14 45 and endogenous synaptosomal PKC activity in situ. 15 As prolonged stimulation of endogenous PKC with phorbol esters or diacylglycerol can promote cPKC translocation and down-regulation, we have analysed the effects of halothane on the subcellular distribution and down-regulation of cPKC in synaptosomes. Our results indicated that halothane alone had no significant effects on PKC translocation and down-regulation; The combination of halothane and the phorbol ester PMA resulted in significant potentiation of both translocation and down-regulation of synaptosomal PKC activity and immunoreactivity observed with PMA alone. These findings suggest that general anaesthetics may potentiate PKC translocation and down-regulation as a result of activation of PKC in vivo. Halothane thus has two distinct actions on the PKC signalling pathway in nerve terminals (synaptosomes): (1) activation of endogenous PKC activity that leads to increased phosphorylation of PKC substrates 15 and (2) potentiation of phorbol esterinduced cPKC translocation and down-regulation. The interactions between general anaesthetics and PKC are therefore complex; the ultimate outcome of these interactions depends on the tissue examined, PKC isoforms present, specific anaesthetic agent, dose and duration of anaesthetic treatment and possibly the coincident activation of PKC by endogenous PKC activators.
